함께 비교하는 진짜 ADC · Antibody · CGT 데이터

AntibodystaleBristol-Myers SquibbPreclinical

nivolumab (Opdivo, Immuno-oncology-based therapy, excluding nivolumab-based regimens, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy)

Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer (NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Preclinical#항체#면역항체+2

AntibodystaleNational University Hospital, S…Phase 1

nivolumab (Opdivo, Oxaliplatin & Nivolumab)

Peritoneal Carcinomatosis · Peritoneal Carcinomatosis

#PeritonealCarcinomatosis#Antibody#Phase1#항체#면역항체+2

AntibodystaleUniversity Hospital, EssenPhase 2

atezolizumab (Tecentriq, mFOLFOX6, Atezolizumab and Bevacizumab)

Biliary Tract Cancer · Biliary Tract Cancer

#BiliaryTractCancer#Antibody#Phase2#항체#면역항체+2

AntibodystaleCentre Leon BerardPhase 2

atezolizumab (Tecentriq, Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery)

Sarcoma,Soft Tissue · Sarcoma,Soft Tissue

#SarcomaSoftTissue#Antibody#Phase2#항체#면역항체+4

AntibodystaleCentre Leon BerardPhase 2

atezolizumab (Tecentriq, Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.)

Sarcoma,Soft Tissue · Sarcoma,Soft Tissue

#SarcomaSoftTissue#Antibody#Phase2#항체#면역항체+4

AntibodystaleEastern Hepatobiliary Surgery H…Phase 3

sequential group (Sequential treatment of bevacizumab combined with atezolizumab, Sequential treatment of bevacizumab combined with atezolizumab (sequential group))

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#HCC-HepatocellularCarcinoma#Antibody#Phase3#항체#면역항체+2

AntibodystaleSamsung Medical CenterPhase 2

atezolizumab (Tecentriq, Pabociclib, Endocrine, Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, Atezolizumab, or ET + CDK4/6 inhibitors)

Premenopausal HR+/HER2- Metastatic Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4

AntibodystaleInnoventPreclinical

Sintilimab combined with Bevacizumab (Sintilimab combined with Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Preclinical#항체#면역항체+2

AntibodystaleAbramson Cancer Center at Penn …Phase 1

atezolizumab (Tecentriq, SBRT + atezolizumab and bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase1#항체#면역항체+2

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2

durvalumab (Imfinzi, Durvalumab (Imfinzi) immunotherapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#Microsatellite-stableColorectalC#Antibody#Phase2#항체#면역항체+2

durvalumab (Imfinzi, E1 - mFOLFOX and durvalumab)

Microsatellite-stable Colorectal Cancer · Microsatellite-stable Colorectal Cancer

#Microsatellite-stableColorectalC#Antibody#Phase2#항체#면역항체+2

durvalumab (Imfinzi, E2 - mFOLFOX6, durvalumab and oleclumab)

Microsatellite-stable Colorectal Cancer · Microsatellite-stable Colorectal Cancer

#Microsatellite-stableColorectalC#Antibody#Phase2#항체#면역항체+2

durvalumab (Imfinzi, E3 - mFOLFOX6, durvalumab and monalizumab)

Microsatellite-stable Colorectal Cancer · Microsatellite-stable Colorectal Cancer

AntibodystaleIntergroupe Francophone de Canc…Phase 2

durvalumab (Imfinzi, Carboplatin + Paclitaxel + Durvalumab)

Small Cell Lung Cancer Extensive Stage · Small Cell Lung Cancer Extensive Stage

#SmallCellLungCancerExtensiveStag#Antibody#Phase2#항체#면역항체+2

AntibodystaleInstitut BergoniéPhase 2

durvalumab (Imfinzi, Association of lurbinectedin and durvalumab)

Small Cell Lung Cancer; Platinum-Sensitive Lung Small Cell Carcinoma · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3

AntibodystaleTianjin Medical University Canc…Phase 2

durvalumab (Imfinzi, HAIC+Durvalumab+Tremelimumab+Bevacizumab)

Unrescetable Hepatocellular Carcinoma · Unrescetable Hepatocellular Carcinoma

#UnrescetableHepatocellularCarcin#Antibody#Phase2#항체#면역항체+2

AntibodystaleAlison StopeckPhase 1

durvalumab (Imfinzi, Abemaciclib, durvalumab and aromatase inhibitor)

Breast Cancer Female; Locally Advanced Breast Cancer · Breast Cancer Female

#BreastCancerFemale#Antibody#Phase1#항체#면역항체+3

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2

Tremelimumab immunotherapy (Tremelimumab immunotherapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#AdvancedSolidTumors#Antibody#Phase2#항체#면역항체+3

MEDI6469 Plus Tremelimumab (MEDI6469 Plus Tremelimumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

효능 ORR 0%임상시험 1상태 DISCONTINUED

#AdvancedSolidTumors#Antibody#Phase2#항체#면역항체+3

durvalumab (Imfinzi, MEDI6469 Plus Durvalumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

효능 ORR 0%임상시험 1상태 DISCONTINUED

#AdvancedSolidTumors#Antibody#Phase2#항체#면역항체+3

MEDI6469 plus Rituximab (MEDI6469 plus Rituximab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

효능 ORR 0%임상시험 1상태 DISCONTINUED

#LargeCellNeuroendocrineCarcinoma#Antibody#Phase2#항체#면역항체+2

durvalumab (Imfinzi, Durvalumab with etoposide and Carboplatin/Cisplatin)

Large Cell Neuroendocrine Carcinoma of the Lung · Large Cell Neuroendocrine Carcinoma of t

#Sarcoma#Antibody#Phase2#항체#면역항체+2

durvalumab (Imfinzi, Durvalumab+doxorubicin cobination)

Sarcoma · Sarcoma

AntibodystaleBeijing Chest HospitalPhase 2

Surufatinib Durvalizumab EP/EC (Surufatinib Durvalizumab EP/EC)

Extensive-stage Small-cell Lung Cancer · Extensive-stage Small-cell Lung Cancer

#Extensive-stageSmall-cellLungCan#Antibody#Phase2#항체#면역항체+2